Amylyx Pharmaceuticals, Inc.
AMLX
Clasificación en acciones
#4255
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Precio por acción
$29.32
Última sincronización: 2026-10-21
Capitalización bursátil
$3.68B
Cambio (1 día)
1.91%
Cambio (1 año)
97.84%
País
US
Comercio Amylyx Pharmaceuticals, Inc. (AMLX)
Categoría
Healthcare
Historial del precio de la acción de Amylyx Pharmaceuticals, Inc. (AMLX)
Precio más alto de cierre: $27.68 el 2026-10-01
Precio más bajo de cierre: $19.75 el 2022-01-01
Precio más bajo de cierre: $19.75 el 2022-01-01
Historial del precio de la acción de Amylyx Pharmaceuticals, Inc. desde 2022 hasta 2026
Desempeño anual del precio de la acción
| Año | Rendimiento |
|---|---|
| 2026 (TTM) | 41.29% |
| 2025 | 192.53% |
| 2024 | -69.40% |
| 2023 | -60.37% |
| 2022 | 0.00% |
Precio de la acción de empresas similares o competidoras
| Empresa | Precio de la acción | Cambio 1a% | País |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $756.75 | 7.56% |
CH
|
